Case definition and phenotype standardization in drug-induced liver injury.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsAithal, G P
Watkins, P B
Andrade, R J
Hunt, C M
Wilke, R A
Daly, A K
MetadataShow full item record
CitationClin. Pharmacol. Ther. 2011, 89(6):806-15
ÚtdrátturDrug-induced liver injury (DILI) is the most frequent reason cited for the withdrawal of approved drugs from the market and accounts for up to 15% of the cases of acute liver failure. Investigators around the globe have begun to identify and study patients with DILI; several large registries and tissue banks are being established. In order to gain the maximum scientific benefit from these efforts, the definitions and terminology related to the clinical phenotypes of DILI must be harmonized. For this purpose, an international DILI Expert Working Group of clinicians and scientists reviewed current DILI terminology and diagnostic criteria so as to develop more uniform criteria that would define and characterize the spectrum of clinical syndromes that constitute DILI. Consensus was established with respect to the threshold criteria for definition of a case as being DILI, the pattern of liver injury, causality assessment, severity, and chronicity. Consensus was also reached on approaches to characterizing DILI in the setting of chronic liver diseases, including autoimmune hepatitis (AIH).
Lu00FDsingTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to Clinical pharmacology and therapeutics
- Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.
- Authors: Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J, DILIN Study Group.
- Issue date: 2009
- Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury.
- Authors: Ozer JS, Chetty R, Kenna G, Palandra J, Zhang Y, Lanevschi A, Koppiker N, Souberbielle BE, Ramaiah SK
- Issue date: 2010 Apr
- Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
- Authors: Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH
- Issue date: 2010 Aug
- Idiosyncratic drug-induced liver injury: an update on the 2007 overview.
- Authors: Hussaini SH, Farrington EA
- Issue date: 2014 Jan
- Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
- Authors: Xu HM, Chen Y, Xu J, Zhou Q
- Issue date: 2012 Nov 7